Using Innovative Financial and Business Models to Speed Science to Patients
Innovative financial and business models are emerging to create a more dynamic market for biomedical advances. Non-profit drug development organizations are promising to use scientific advances to help poor and underserved populations. Spin-outs from large biopharmaceutical companies are opening up new sources of capital to ensure that valuable science progresses for patients.
Shortages in generics are being eliminated through innovative arrangements, ensuring stable supply for hospitals and those who need them. In short, a wave of trailblazers is beginning to address what ails us and helping to optimize the societal value of our collective investment in science.
During this webinar, we will explore the challenges that these innovators are addressing, as well as the solutions that are surfacing. Compounds with promising science but lower commercial prospects are often deprioritized within pipelines. How can we unlock new sources of capital and create new channels to develop these valuable compounds for patients? Incentives can be weak for generics manufacturers to produce a stable supply of critical medicines at prices palatable to hospital systems. How could incentives be better aligned to address the needs of all stakeholders in the system? Overall, we will explore how we can learn from and expand promising financial and business models that have the potential to transform the landscape for biomedical advances.
• Freda Lewis-Hall, Executive Vice President and CMO, Pfizer
• Dan Liljenquist, Senior Vice President and Chief Strategy Officer at Intermountain Healthcare, Chair of Civica Rx
• Colleen Rye, Director, FasterCures, a center of the Milken Institute
• Tanisha Carino, Executive Director, FasterCures, a center of the Milken Institute (moderator)